AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (withdrawn): A medicine for the prevention or treatment of urinary frequency or incontinence, which comprises combination of a phenoxyacetic acid derivative represented by a general formula:



(I)

wherein R1 represents a hydroxy group or a lower alkoxy group, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof and an α1-adrenoceptor blocker.

2. (withdrawn): A medicine as claimed in claim 1 wherein the phenoxyacetic acid derivative represented by the general formula (I) is ethyl (-)-2-[4-[2-[[(1S, 2R)-2-hydroxy-2-(4-hydroxyphenyl)-1- methylethyl]amino]ethyl]-2,5-dimethylphenoxy]acetate.

3. (withdrawn): A medicine as claimed in claim 1 or 2 wherein the α1 adrenoceptor blocker is silodosin, tamsulosin, prazosin, terazosin or naftopidil, or pharmaceutically acceptable salt thereof.

4. (withdrawn): A medicine as claimed in claim 3 wherein the α1 adrenoceptor blocker is silodosin or tamsulosin, or a pharmaceutically acceptable salt thereof.

5. (withdrawn): A medicine as claimed in claim 3 wherein the dosage of prazosin or a pharmaceutically acceptable salt thereof is 1 to 12 mg/day as oral dose of prazosin hydrochloride for an adult human.

6. (withdrawn): A medicine as claimed in claim 3 wherein the dosage of naftopidil or a pharmaceutically acceptable salt thereof is 25 to 150 mg/day as oral dose of naftopidil for an adult human.

7. (withdrawn): A medicine as claimed in claim 4 wherein the dosage of silodosin or a pharmaceutically acceptable salt thereof is 1 to 16 mg/day as oral dose of silodosin for an adult human.

8. (withdrawn): A medicine as claimed in claim 4 wherein the dosage of tamsulosin or a pharmaceutically acceptable salt thereof is 0.1 to 0.8 mg/day as oral dose of tamsulosin hydrochloride for an adult human.

9. (withdrawn): A combination formulation for the prevention or treatment of urinary frequency or incontinence, which comprises a phenoxyacetic acid derivative represented

by the general formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof and an α1-adrenoceptor blocker.

10. (withdrawn): An enhancing agent of an efficacy of a phenoxyacetic acid derivative represented by the general formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof for the prevention or treatment of urinary frequency or incontinence, which comprises as an active ingredient an α1-adrenoceptor blocker.

11. (currently amended): A method for the treatment of urinary frequency or incontinence, comprising administering to a subject not having benign prostatic hyperplasia or symptomatic prostatism a phenoxyacetic acid derivative represented by a general formula (I):



(I)

wherein R1 represents a hydroxy group or a lower alkoxy group, or a pharmaceutically acceptable salt thereof in combination with an α1-adrenoceptor blocker.

12. (previously presented): A method as claimed in claim 11 wherein the phenoxyacetic acid derivative represented by the general formula (I) is ethyl(-)-2-[4-[2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-ethylethyl]amino]ethyl]-2,5-dimethylphenoxy]acetate.

13. (previously presented): A method as claimed in claim 11 or 12 wherein the α1-adrenoceptor blocker is silodosin, tamsulosin, prazosin, terazosin or naftopidil, or a pharmaceutically acceptable salt thereof.

14. (previously presented): A method as claimed in claim 13 wherein the α1-adrenoceptor blocker is silodosin or tamsulosin, or a pharmaceutically acceptable salt thereof.

15. (withdrawn): A method as claimed in claim 13 wherein a dosage of prazosin or a pharmaceutically acceptable salt thereof is 1 to 12 mg/day as oral dose of prazosin hydrochloride for an adult human.

16. (withdrawn): A method as claimed in claim 13 wherein a dosage of naftopidil or a pharmaceutically acceptable salt thereof is 25 to 150 mg/day as oral dose of naftopidil for an adult human.

17. (previously presented): A method as claimed in claim 14 wherein a dosage of silodosin or a pharmaceutically acceptable salt thereof is 1 to 16 mg/day as oral dose of silodosin for an adult human.

18. (withdrawn): A method as claimed in claim 14 wherein a dosage of tamsulosin or a pharmaceutically acceptable salt thereof is 0.1 to 0.8 mg/day as oral dose of tamsulosin hydrochloride for an adult human.

19. (currently amended): A method for the treatment of urinary frequency which comprises administering to a subject not having benign prostatic hyperplasia or symptomatic prostatism a phenoxyacetic acid derivative represented by the general formula (I):



(I)

wherein R1 represents a hydroxy group or a lower alkoxy group, or a pharmaceutically acceptable salt thereof, in combination with silodosin.